AI Article Synopsis
- Lymphopenia, a condition where lymphocyte (a type of white blood cell) levels are low, is often found in sepsis patients and is linked to higher mortality rates.
- The study examined if lymphopenia could be a reliable indicator of outcomes in patients with bacteremia, involving 574 individuals from two hospitals.
- Results showed that initial lymphocyte counts and changes over the first four days did not predict 12-week mortality, suggesting the need for a better understanding of each patient’s immune profile before pursuing immune therapies.
Article Abstract
Lymphopenia is common in patients with sepsis and associated with mortality. Immune-stimulatory therapies likely to restore T-cells count and function are under investigation in sepsis. Our study aimed to assess whether lymphopenia is a reliable prognostic biomarker in bacteremia. We conducted an ancillary study of the prospective VIRSTA Study including 574 patients with bacteremia in two tertiary care centers. Neither lymphocyte count at the onset nor lymphocyte change during the first 4 days was associated with 12-week mortality. These results highlight the importance of characterizing the immune profile of patients with sepsis according to the cause before investigating immunostimulatory therapies to restore lymphocyte proliferation and function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jim-2022-002356 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Utility of Interferon-γ Release Assays in the Diagnosis of Tuberculosis in Patients With Cancer.
Transpl Infect Dis
December 2024
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Patients with cancer are at elevated risk for tuberculosis (TB) reactivation. Diagnosis of latent TB infection and TB disease remains challenging in this patient population despite the advent of interferon-γ release assays (IGRA).
Methods: We retrospectively reviewed medical records of all patients with cancer who had IGRA testing (QuantiFERON-TB [QFT-TB] or T-SPOT.
Evaluation of the hematological parameters, inflammatory biomarkers, and thyroid hormones in hypothyroidism patients.
BMC Res Notes
December 2024
Department of Immunology, Faculty of Medicine, Kazerun Branch, Islamic Azad University, Kazerun, Iran.
Aim: Hypothyroidism is created by disruption of thyroid hormone production, which can destroy the emotional, relational, social, and working life of patients if left untreated. Hypothyroidism has multiple etiologies. We evaluated the relationship of hematological parameters and inflammatory biomarkers with thyroid hormones to find the potential use of these items in patients screening and prognosis.
View Article and Find Full Text PDFImpact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy.
Sci Rep
December 2024
Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Renorrhaphy is often performed after tumor resection during robotic-assisted laparoscopic partial nephrectomy (RAPN). This study aimed to investigate the association between renorrhaphy performance and inflammatory markers. A retrospective cohort study was conducted including patients with renal cell carcinoma who underwent RAPN at eight institutions in Japan between April 2016 and November 2023.
View Article and Find Full Text PDFFunctional status, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio as prognostic factors of one-year survival rate in elderly patients with advanced-stage non-small cell lung cancer.
Cancer Treat Res Commun
December 2024
Dharmais National Cancer Center Hospital, Jakarta, Indonesia. Electronic address:
Background And Aim: Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. Aging and chronic inflammation are related to its pathogenesis. Functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio describe a chronic inflammation and correlate to the survival of older adults with advanced-stage (IIIB-IV) NSCLC.
View Article and Find Full Text PDFWhole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis.
Mult Scler Relat Disord
December 2024
Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic.
Background: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!